Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yangfeng Ge"'
Autor:
Guangfeng Wang, Eric Liang, Ping Min, Yangfeng Ge, Bingxing Wu, Huidan Yu, Dajun Yang, Yifan Zhai
Publikováno v:
Blood. 140:9953-9954
Autor:
Eric Liang, Ping Ming, Fei Zhang, Lvcheng Wang, Guangfeng Wang, Yangfeng Ge, Jingjin Shang, Jing Lv, Li Rui, Yifan Zhai, Dajun Yang, Chunyang Tang
Publikováno v:
Blood. 138:2062-2062
Natural killer/T-cell lymphoma (NK/TCL) is one of the most common subtypes (10.4%) of peripheral T-cell lymphoma, which in turn accounts for 10% to 15% of all cases of non-Hodgkin lymphoma. NK/TCL occurs more frequently in Asia and Latin America than
Autor:
Chunyang Tang, Fei Zhang, Ping Min, Kejie Lian, Lvcheng Wang, Jing Lv, Eric Liang, Yifan Zhai, Li Rui, Guangfeng Wang, Yangfeng Ge, Dajun Yang
Publikováno v:
Cancer Research. 81:1463-1463
Treatment with tyrosine kinase inhibitors (TKIs) directed against the ATP-binding site of BCR-ABL promotes recovery of Ph+ leukemia. However, emergence of gatekeeper mutation T315I and compound mutants confer resistance to these TKIs. The allosteric
Autor:
Danyi Wen, Yangfeng Ge, Ran Tao, Yifan Zhai, Miaoyi Wu, Yuanbao Li, Guangfeng Wang, Dajun Yang, Feifei Zhang, Jing Lv, Guoqin Zhai, Douglas D. Fang
Publikováno v:
Cancer Research. 80:6223-6223
Osimertinib (AZD9291) is the first-line treatment for EGFR-mutated NSCLC; however, the majority of patients inevitably develop resistance due to de novo genomic abnormalities, such as C797S mutation, EGFR exon 20 insertion, MET amplification and othe
Publikováno v:
International Journal of Nanomedicine, Vol 2012, Iss default, Pp 581-589 (2012)
International Journal of Nanomedicine
International Journal of Nanomedicine
Danbo Yang1, Sang Van2, Yingyi Shu1, Xiaoqing Liu1, Yangfeng Ge1, Xinguo Jiang3, Yi Jin2, Lei Yu1,21Biomedical Engineering and Technology Institute, Institutes for Advanced Interdisciplinary Research, East China Normal University, Shanghai, People’